Year in review 2013: Paediatric and adult clinical studies

Thorax

Volumn 69, Issue 4, 2014, Pages 309-311

  Bush, Andy ^a   Pavord, Ian ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZITHROMYCIN; BECLOMETASONE DIPROPIONATE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; METFORMIN; PREDNISOLONE; SALBUTAMOL; STEROID;

ASTHMA; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; EDITORIAL; HUMAN; HYPERGLYCEMIA; INTERSTITIAL LUNG DISEASE; LUNG CANCER; LUNG DISEASE; LUNG INFECTION; LUNG NON SMALL CELL CANCER; MYCOBACTERIUM TUBERCULOSIS; OBESITY; OUTCOME ASSESSMENT; PATIENT CARE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PULMONARY REHABILITATION; RISK ASSESSMENT; SLEEP DISORDERED BREATHING; SPIROMETRY;

NOT APPLICABLE;

ADULT; BIOMEDICAL RESEARCH; CHILD; HUMANS; PEDIATRICS; PULMONARY MEDICINE;

EID: 84896765479     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-205222     Document Type: Editorial

References (59)

1. Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013;68:818-25.
2. Schuster A, Haliburn C, Döring G, et al. Freedom Study Group. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013;68:344-50.
3. Southern KW, McCormack P, McNamara PS. After a long wait, two arrive, one after the other! Thorax 2013;68:311-12.
4. Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68:812-17.
5. McIlwaine MP, Alarie N, Davidson GF, et al. Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. Thorax 2013;68:746-51.
6. Main E. Airway clearance research in CF: the 'perfect storm' of strong preference and effortful participation in long-term, non-blinded studies. Thorax 2013;68:701-2.
7. Byrnes CA, Vidmar S, Cheney JL, et al. Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. Thorax 2013;68:643-51.
8. Sanders DB, Hoffman LR, Emerson J, et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010;45:127-34.
9. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:627-32.
10. Sanders DB, Bittner RC, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011;46:393-400.
11. de Boer K, Vandemheen KL, Tullis E, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011;66:680-5.
12. Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012;40:61-6.
13. Nick JA, Sanders LA, Ickes B, et al. Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis. Thorax 2013;68:929-37.
14. Horsley AR, Davies JC, Gray RD, et al. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 2013;68: 532-9.
15. Baxter CG, Rautemaa R, Jones AM, et al. Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum. Thorax 2013;68:652-7.
16. Abbott J, Hurley MA, Morton AM, et al. Longitudinal association between lung function and health-related quality of life in cystic fibrosis. Thorax 2013;68:149-54.
17. Ling DI, Nicol MP, Pai M, et al. Incremental value of T-SPOT.TB for diagnosis of active pulmonary tuberculosis in children in a high-burden setting: a multivariable analysis. Thorax 2013;68:860-6.
18. Mandalakas AM, Hesseling AC, Gie RP, et al. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax 2013;68:247-55.
19. Bolton CE, Bush A, Hurst JR, et al. Are early life factors considered when managing respiratory disease? A British Thoracic Society survey of current practice. Thorax 2012;67:1110.
20. Bolton CE, Bush A. Coming now to a chest clinic near you. Thorax 2013;68:707-8.
21. Kotecha S, Davies PL, Clark HW, et al. Increased prevalence of low oligomeric state surfactant protein D with restricted lectin activity in bronchoalveolar lavage fluid from preterm infants. Thorax 2013;68:460-7.
22. Kotecha SJ, Edwards MO, Watkins WJ, et al. Effect of preterm birth on later FEV1: a systematic review and meta-analysis. Thorax 2013;68:760-6.
23. Vollsæter M, Røksund OD, Eide GE, et al. Lung function after preterm birth: development from mid-childhood to adulthood. Thorax 2013;68:767-76.
24. Jennum P, Ibsen R, Kjellberg J. Morbidity and mortality in children with obstructive sleep apnoea: a controlled national study. Thorax 2013;68:949-54.
25. Edwards CA, Osman LM, Godden DJ, et al. Wheezy bronchitis in childhood: a distinct clinical entity with lifelong significance? Chest J 2003;124:18-24. (Pubitemid 36851326)
26. Pike KC, Inskip HM, Robinson SM, et al. The relationship between maternal adiposity and infant weight gain, and childhood wheeze and atopy. Thorax 2013;68:372-9.
27. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of cotrimoxazole: a randomised controlled trial. Thorax 2013;68:155-62.
28. Garzoni C, Brugger SD, Qi W, et al. Microbial communities in the respiratory tract of patients with interstitial lung disease. Thorax 2013;68:1150-6.
29. Rogers GB, van der Gast CJ, Cuthbertson L, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013;68:731-7.
30. Patel AS, Siegert RJ, Creamer D, et al. The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax 2013;68:57-65.
31. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012;67:804-10.
32. Powell HA, Tata LJ, Baldwin DR, et al. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit. Thorax 2013;68:826-34.
33. Agostini P, Naidu B, Cieslik H, et al. Effectiveness of incentive spirometry in patients following thoracotomy and lung resection including those at high risk for developing pulmonary complications. Thorax 2013;68:580-5.
34. Browaldh N, Nerfeldt P, Lysdahl M, et al. SKUP3 randomised controlled trial: polysomnographic results after uvulopalatopharyngoplasty in selected patients with obstructive sleep apnoea. Thorax 2013;68:846-53.
35. Rossi VA, Winter B, Rahman NM, et al. The effects of Provent on moderate to severe obstructive sleep apnoea during continuous positive airway pressure therapy withdrawal: a randomised controlled trial. Thorax 2013;68:854-9.
36. Vanderveken OM, Dieltjens M, Wouters K, et al. Objective measurement of compliance during oral appliance therapy for sleep-disordered breathing. Thorax 2013;68:91-6.
37. Ciccone A, Proserpio P, Roccatagliata DV, et al. Wake-up stroke and TIA due to paradoxical embolism during long obstructive sleep apnoeas: a cross-sectional study. Thorax 2013;68:97-104.
38. Busse WW, O'Byrne PM, Bleecker ER, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial. Thorax 2013;68:513-20.
39. Aaron SD, Vandemheen KL, Maltais F, et al. TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax 2013;68:142-8.
40. Edwards L, Shirtcliffe P, Wadsworth K, et al. Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax 2013;68:338-43.
41. MacNee W, Allan RJ, Jones I, et al. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 2013;68:738-45.
42. Brusselle GG, VanderStichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322-9.
43. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012;186:48-55.
44. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012;67:970-6.
45. Kupczyk M, Haque S, Sterk PJ, et al. Detection of exacerbations in asthma based on electronic diary data: results from the 1-year prospective BIOAIR study. Thorax 2013;68:611-18.
46. Volbeda F, Broekema M, Lodewijk ME, et al. Clinical control of asthma associates with measures of airway inflammation. Thorax 2013;68:19-24.
47. van der Sluijs KF, van de Pol MA, Kulik W, et al. Systemic tryptophan and kynurenine catabolite levels relate to severity of rhinovirus-induced asthma exacerbation: a prospective study with a parallel-group design. Thorax 2013;68:1122-30.
48. Seys SF, Daenen M, Dilissen E, et al. Effects of high altitude and cold air exposure on airway inflammation in patients with asthma. Thorax 2013;68:906-13.
49. Jones SE, Kon SSC, Canavan JL, et al. The five-repetition sit-to-stand test as a functional outcome measure in COPD. Thorax 2013;68:1015-20.
50. Donaldson A, Natanek SA, Lewis A, et al. Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax 2013;68:1140-9.
51. Constantin D, Menon MK, Houchen-Wolloff L, et al. Skeletal muscle molecular responses to resistance training and dietary supplementation in COPD. Thorax 2013;68:625-33.
52. Casey D, Murphy K, Devane D, et al. The effectiveness of a structured education pulmonary rehabilitation programme for improving the health status of people with moderate and severe chronic obstructive pulmonary disease in primary care: the PRINCE cluster randomised trial. Thorax 2013;68:922-8.
53. Andréjak C, Nielsen R, Thomsen VØ, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013;68:256-62.
54. Lee C-H, Kim K, Hyun MK, et al. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013;68:1105-13.
55. Singanayagam A, Manalan K, Sridhar S, et al. Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy. Thorax 2013;68:955-61.
56. Theron G, Peter J, Meldau R, et al. Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax 2013;68:1043-51.
57. Naucler P, Darenberg J, Morfeldt E, et al. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 2013;68:571-9.
58. Chalmers JD, McHugh BJ, Docherty C, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013;68:39-47.
59. Garnett JP, Baker EH, Naik S, et al. Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose. Thorax 2013;68:835-45.